-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Type I diabetes is an autoimmune β characterized by the gradual loss of function of islet cells.
Golumab is a human-based monoclonal antibody α against the cause of tumor necrotization, which can be used to treat a variety of autoimmune diseases in adults and children.
researchers recently examined the effects on cellular function in newly diagnosed young people with type 3 β type 3 diabetes.
In this Phase II, multi-center, placebo-controlled, double-blind, parallel group trial, children and young people newly diagnosed with type 1 diabetes (age range, 6 to 21 years old) received subsuperective injections of Golimumab or placebo for 52 weeks.
end points of the study were endogenic insulin production (assessed based on the concentration-time curve area at the C peptide level) and the 52nd week 4-hour mixed dietary tolerance test (4-hour C peptide AAUC) reaction.
secondary and additional endpoints include insulin use, glycation hemoglobin levels, hypoglycemia events, and changes in the ratio of peri-abdominal insulin to C peptides.
84 patients in the study, including 56 in the Golumumab group and 28 in the placebo group.
week 52, there was a significant difference in the average 4-hour C peptide AAUC between the Goliumumab group and the placebo group (0.64 vs. 0.43 pmol/ml).
insulin use in the Golumumab group was lower than in the placebo group.
in the Golumumab group, 43 percent of the participants observed partial remission, while only 7 percent in the placebo group.
there was a significant difference in the risk of hypoglycemia events between the two groups, with 13 participants (23%) in the Golimumab group having hypoglycemia events (23%) and 2 (7%) having hypoglycemia events in the placebo group.
antibodies against Golumumab were detected in 30 patients, and 29 participants had antibody effectiveness of less than 1:1000, of which 12 were positive for meso-antibodies.
study, Golimumab therapy can improve endogen insulin production and reduce the use of extrogenic insulin in people with type 1 diabetes.